Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $9.50.

Several equities research analysts recently issued reports on the company. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Wedbush lifted their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Morgan Stanley reiterated an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a report on Friday, March 13th. Wall Street Zen cut Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Sunday, June 7th. Finally, Zacks Research cut Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd.

Sana Biotechnology Trading Down 3.2%

SANA stock opened at $2.68 on Friday. Sana Biotechnology has a 12-month low of $2.41 and a 12-month high of $6.55. The stock has a market cap of $745.82 million, a price-to-earnings ratio of -2.88 and a beta of 2.14. The business’s 50-day moving average is $3.22 and its 200 day moving average is $3.79.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. As a group, equities analysts forecast that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SANA. Royal Bank of Canada boosted its holdings in shares of Sana Biotechnology by 76.8% during the 1st quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock worth $35,000 after purchasing an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $36,000. Lyell Wealth Management LP acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $37,000. Rockefeller Capital Management L.P. boosted its holdings in shares of Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock worth $39,000 after purchasing an additional 4,088 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $39,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.